Drug Profile
Research programme: rheumatoid arthritis stem cell therapies - Benitec Biopharma/Precigen Inc
Latest Information Update: 11 Feb 2020
Price :
$50
*
At a glance
- Originator Benitec Ltd; MediStem Laboratories
- Developer Benitec Biopharma; Medistem
- Class Gene therapies; Stem cell therapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 03 Feb 2020 Intrexon Corporation is now called Precigen Inc
- 12 Mar 2014 No development reported - Preclinical for Rheumatoid arthritis in Australia (Parenteral)
- 12 Mar 2014 No development reported - Preclinical for Rheumatoid arthritis in USA (Parenteral)